ImmunityBio, Inc. Common Stock
IBRX
$6.99
+4.02%
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate both the innate and adaptive immune systems to fight cancer and infectious diseases. Its core platform, Cancer BioShield, is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio of adenovirus-vectored vaccines, NK-cell therapies, and immunomodulators. The current investor narrative is dominated by the company's transition from a clinical-stage entity to a commercial one, driven by recent regulatory milestones and commercial launches for its lead asset. Recent news highlights include the FDA's acceptance of a filing to expand ANKTIVA's use in bladder cancer and the drug's approval in the European Union, which are critical catalysts driving significant investor attention and debate around the stock's growth trajectory and commercial execution.…
IBRX
ImmunityBio, Inc. Common Stock
$6.99
Related headlines
Investment Opinion: Should I buy IBRX Today?
Rating: Hold. The core thesis is that while ANKTIVA's launch is promising and the forward valuation is compelling, the extreme binary risk, high cash burn, and recent technical weakness warrant caution until commercial execution is more proven.
Supporting evidence for this neutral stance is mixed. On the positive side, Q4 revenue growth of 407% YoY is exceptional, gross margins of 88.91% are best-in-class, and the forward PS ratio of ~0.75x (based on a $2.42B revenue estimate) suggests massive embedded upside. However, these are counterbalanced by a deeply negative TTM FCF of -$308M, a net loss margin of -161.8%, and a stock price that has declined 15.92% over three months, indicating a loss of momentum post-catalyst. The lack of broad analyst consensus further muddies the valuation picture.
The two biggest risks that could invalidate a more bullish view are 1) a slowdown in quarterly revenue sequential growth, and 2) the necessity of a highly dilutive equity offering within the next 12 months. This Hold rating would upgrade to a Buy if the company demonstrates sustained quarterly revenue acceleration toward the $2.42 billion annualized run rate while concurrently reducing its quarterly cash burn. It would downgrade to a Sell if quarterly revenue growth stalls below 20% sequentially or if the company announces a large capital raise at a significant discount to the current price. Relative to its own history, the stock is fairly valued as it transitions from speculative pre-revenue multiples to commercial-stage metrics, but it remains a high-risk, high-reward proposition.
Sign up to view all
IBRX 12-Month Price Forecast
The outlook for IBRX is a classic biotech binary, skewed slightly positive by early launch metrics but heavily tempered by financial risk. The base case of volatile consolidation is most likely, as the market digests quarterly sales data against high expectations. The bull case, while offering substantial upside, requires flawless execution in a challenging environment. The bear case is a tangible threat given the cash burn and single-asset dependence. The stance would upgrade to bullish on confirmation of revenue accelerating toward the $2.42 billion estimate while cash burn improves. It would turn bearish on any indication that sequential revenue growth is stalling below 20% per quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ImmunityBio, Inc. Common Stock's 12-month outlook, with a consensus price target around $9.09 and implied upside of +30.0% versus the current price.
Average Target
$9.09
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$6 - $9
Analyst target range
Analyst coverage for ImmunityBio appears to be limited, with data indicating only one analyst providing estimates. The consensus revenue estimate for the next period is $2.42 billion, with a range from $1.64 billion to $3.44 billion. This wide range underscores the high uncertainty surrounding the commercial uptake of ANKTIVA. The single analyst's EPS estimate is $1.27, but given the minimal coverage, a formal consensus recommendation and target price are not reliably available from the provided dataset. The implications of limited analyst coverage are significant. It typically indicates the stock is a small-to-mid-cap name with high binary risk, leading to less efficient price discovery and higher volatility. The wide revenue estimate range from the single analyst reflects the substantial uncertainty in forecasting the launch trajectory. Investors should note that the lack of broad institutional analyst coverage increases the onus on individual due diligence, as there is less professional scrutiny and consensus to guide valuation. The recent institutional ratings from the data show a series of 'Buy' or 'Overweight' reiterations from firms like HC Wainwright and Piper Sandler in early 2026, coinciding with regulatory news, but a comprehensive consensus view is not established.
Bulls vs Bears: IBRX Investment Factors
The bull and bear cases for ImmunityBio are starkly defined, with the bear side currently presenting stronger near-term evidence due to the stock's post-catalyst consolidation, high short interest, and persistent deep losses. The bulls' thesis rests entirely on the future commercial success of ANKTIVA, supported by explosive early revenue growth and major regulatory wins. The bears highlight the unsustainable cash burn, single-asset risk, and leveraged balance sheet. The single most important tension in the investment debate is the timing and magnitude of ANKTIVA's revenue ramp relative to the company's cash burn rate. If revenue accelerates toward the analyst's $2.42 billion estimate, the stock is profoundly undervalued. If execution falters or is delayed, the need for dilutive financing could trigger a severe decline.
Bullish
- Explosive Revenue Growth Trajectory: Q4 2025 revenue grew 407% year-over-year to $38.3 million, accelerating sequentially from $16.5 million in Q1 2025. This demonstrates a successful commercial launch ramp for ANKTIVA, transitioning the company from a clinical-stage entity to a commercial one.
- High Gross Margin & Operating Leverage: The company boasts an exceptionally high gross margin of 88.91% for Q4 2025, typical for an approved biologic. The net loss margin improved dramatically to -161.8% from -783.4% a year ago, showing initial signs of operating leverage as revenue scales.
- Major Regulatory & Commercial Catalysts: Recent news includes FDA acceptance for expanded ANKTIVA use in bladder cancer and EU approval, opening significant new markets. These milestones validate the clinical data and are critical drivers for future revenue growth beyond the initial launch.
- Attractive Forward Valuation on Growth: Based on a single analyst's consensus revenue estimate of $2.42 billion for the next period, the stock trades at a forward Price-to-Sales ratio of approximately 0.75x. This low multiple prices in massive sales growth, offering significant upside if execution succeeds.
Bearish
- Deep & Sustained Cash Burn: The company reported a TTM free cash flow of -$308.0 million and a Q4 2025 net loss of $61.9 million. This severe cash burn rate necessitates future capital raises, risking shareholder dilution and financial instability if revenue growth stalls.
- Extreme Dependence on Single Asset: Virtually all current revenue ($38.3M in Q4) comes from the product segment, i.e., ANKTIVA. The entire investment thesis hinges on the successful commercial execution and label expansion of this one drug, creating high binary risk.
- High Short Interest & Recent Weakness: With a short ratio of 10.37, a significant portion of the float is betting against the stock. Recent price action confirms skepticism, with the stock down 15.92% over 3 months and trading 42% below its 52-week high of $12.43, indicating profit-taking and consolidation.
- Negative Profitability & Leveraged Balance Sheet: The company has negative net income, negative EBITDA (-$31.0M in Q4), and a negative debt-to-equity ratio of -1.76. This indicates more liabilities than equity, a high-risk financial structure common in capital-intensive biotechs.
IBRX Technical Analysis
The stock is in a powerful long-term uptrend but has recently entered a consolidation phase. Over the past year, the stock has surged by 148.81%, a massive move driven by regulatory catalysts. As of the latest close at $7.29, the price is trading at approximately 42% of its 52-week high of $12.43, having retreated significantly from its February peak. This positioning suggests the explosive momentum has cooled, and the stock is now consolidating gains, trading closer to the middle of its 52-week range (with a low of $1.95). Recent momentum shows a clear divergence from the longer-term uptrend, indicating a significant pullback. The stock is down 3.83% over the past month and down 15.92% over the past three months, contrasting sharply with the positive one-year performance. This deceleration and recent decline suggest a period of profit-taking and consolidation following the parabolic move earlier in the year, as the market digests the recent news and awaits further commercial execution data. Key technical support is anchored at the 52-week low of $1.95, while immediate resistance is at the recent highs near $12.43. A breakout above the $12.43 level would signal a resumption of the primary bull trend, whereas a breakdown below the $7.00-$6.50 consolidation zone could lead to a test of lower support levels. The stock's beta of 0.073 is exceptionally low relative to the market, indicating it has exhibited dramatically lower volatility than the S&P 500 over the measured period, though this may not fully capture the extreme volatility seen in its price spikes earlier in 2026.
Beta
0.10
0.10x market volatility
Max Drawdown
-42.4%
Largest decline past year
52-Week Range
$2-$12
Price range past year
Annual Return
+146.1%
Cumulative gain past year
| Period | IBRX Return | S&P 500 |
|---|---|---|
| 1m | -12.6% | +0.3% |
| 3m | -20.7% | +12.3% |
| 6m | +236.1% | +8.9% |
| 1y | +146.1% | +24.0% |
| ytd | +246.0% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBRX Fundamental Analysis
Revenue is in its nascent stage but showing significant sequential growth, indicative of a commercial launch ramp. For Q4 2025, the company reported revenue of $38.3 million, representing a year-over-year growth of 407% from a very small base of $7.6 million in Q4 2024. The quarterly trend shows accelerating growth, with revenue increasing from $16.5 million in Q1 2025 to $38.3 million in Q4 2025. This trajectory is being driven by the initial commercial launch of ANKTIVA, with the 'Product' segment contributing $38.3 million of the total, signaling the transition from a development-stage company to a commercial entity. The company remains deeply unprofitable as it invests heavily in its commercial launch and R&D. For Q4 2025, it reported a net loss of $61.9 million and an EBITDA loss of $31.0 million. However, the gross margin is exceptionally high at 88.91% for the quarter, which is typical for an approved biologic therapy. The net loss margin of -161.8% for the quarter, while still severe, shows improvement from the -783.4% net margin in Q4 2024, indicating operating leverage is beginning to materialize as revenue scales. The balance sheet shows a high-risk financial profile typical of a commercializing biotech. The company has a negative debt-to-equity ratio of -1.76, indicating it has more liabilities than equity, a common structure for firms that have raised significant capital through convertible debt. The current ratio is strong at 5.10, suggesting ample short-term liquidity. However, free cash flow over the trailing twelve months is deeply negative at -$308.0 million, reflecting the substantial cash burn required to fund operations and growth. The Return on Equity (ROE) of 70.34% is mathematically positive but is a result of a very small or negative equity base and is not indicative of sustainable profitability.
Quarterly Revenue
$38285000.0B
2025-12
Revenue YoY Growth
+4.06%
YoY Comparison
Gross Margin
+0.88%
Latest Quarter
Free Cash Flow
$-308007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBRX Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is 16.08x, based on the latest quarterly revenue annualized. The forward-looking valuation is more relevant, with analyst consensus estimating revenue of $2.42 billion for the next fiscal period, which would imply a forward PS ratio of approximately 0.75x based on the current market cap of $1.82 billion, signaling the market is pricing in massive future sales growth. Peer comparison is challenging due to the lack of direct, profitable commercial-stage peers with similar platforms. However, the trailing PS ratio of 16.08x is elevated compared to many established biotech firms but can be justified for a company with a recently approved, first-in-class therapy and a large addressable market. The valuation is entirely predicated on the successful commercial execution and pipeline expansion of ANKTIVA, rather than current financials. Historical context shows the valuation has compressed dramatically as revenue has begun to materialize. For instance, the PS ratio was 51.18x at the end of Q4 2025 and has been as high as 89,000x in early 2024 when revenue was negligible. The current PS multiple of 16.08x represents a significant de-risking from its pre-revenue levels and reflects the market's gradual shift from valuing the company on pipeline potential to actual commercial sales. The stock is trading well below its historical peak valuations, which were based on speculative potential, and is now being valued on early launch metrics.
PE
-5.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -29x~-2x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's cash position. With trailing twelve-month free cash flow at -$308 million and a Q4 2025 net loss of $61.9 million, the company is burning cash at an alarming rate to fund its commercial launch and R&D. The negative debt-to-equity ratio of -1.76 indicates a leveraged balance sheet where liabilities exceed equity, a structure that becomes precarious if revenue growth disappoints. The investment case is entirely dependent on ANKTIVA's success, as 100% of product revenue is from this single asset, creating extreme concentration risk. Any clinical setback, slower-than-expected market adoption, or reimbursement issue could cripple the financial model.
Market & Competitive Risks include valuation compression from its current levels. While the forward PS ratio of ~0.75x seems low, the trailing PS of 16.08x is elevated for a company with minimal profit. The stock's beta of 0.073 is misleadingly low, as the price has shown extreme volatility, surging 148% in a year but also experiencing a max drawdown of -42.44%. The high short interest of 10.37 signals deep skepticism from sophisticated investors about the company's ability to execute. Furthermore, the biotechnology sector is fiercely competitive and subject to rapid innovation; ANKTIVA's commercial success is not guaranteed against existing or future therapies.
Worst-Case Scenario involves a combination of commercial execution missteps and a tightening capital market. If ANKTIVA's sales growth decelerates significantly in the next two quarters, missing the steep trajectory implied by the $2.42 billion analyst estimate, investor confidence would collapse. This could trigger analyst downgrades, force the company to raise capital at a severely depressed share price, and lead to a vicious cycle of dilution and selling. In this adverse scenario, the stock could realistically retest its 52-week low of $1.95, representing a downside of approximately -73% from the current price of $7.29. The path to this low is evidenced by the stock's trading history in late 2025 before the regulatory catalysts emerged.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is burning cash at a rate of -$308 million TTM and has a negative debt-to-equity ratio, necessitating future dilutive financing. 2) Commercial/Execution Risk: The entire thesis depends on one drug, ANKTIVA; slower-than-expected sales growth or market adoption would collapse the valuation. 3) Competitive & Clinical Risk: The biotechnology landscape is dynamic, and any adverse clinical data or superior competitor therapy could impair ANKTIVA's commercial potential. 4) Sentiment & Volatility Risk: With a short ratio of 10.37 and limited analyst coverage, the stock is prone to sharp swings on news and sentiment.
The 12-month forecast for IBRX is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $7.50 and $10.00 as commercial execution meets moderate expectations. The Bull Case (25% probability) could drive the stock to its 52-week high of $12.43 and beyond, toward $16.00, if revenue growth dramatically exceeds forecasts. The Bear Case (25% probability) could see the stock retesting its 52-week low of $1.95, falling to the $4.00 range, if execution falters and dilution occurs. The most likely outcome is the Base Case, contingent on ANKTIVA's quarterly sales maintaining a steady sequential growth pace.
IBRX's valuation is a tale of two metrics, making it difficult to classify simply. Based on trailing sales, it appears expensive with a PS ratio of 16.08x. However, based on forward analyst estimates of $2.42 billion in revenue, it appears deeply undervalued with a forward PS of ~0.75x. This dichotomy shows the market is pricing in massive future growth. Compared to its own history, the valuation has de-risked significantly from pre-revenue levels. The stock is fairly valued for the high-risk, high-reward commercial-stage biotech profile it represents, with the current price reflecting a balanced probability of success and failure.
IBRX is a speculative buy only for investors with a high risk tolerance and a long-term investment horizon. The potential reward is significant, with a forward Price-to-Sales ratio of approximately 0.75x based on analyst estimates of $2.42 billion in revenue, implying substantial upside if execution succeeds. However, the risks are equally large, including a TTM free cash flow burn of -$308 million, dependence on a single drug, and a stock price that has retreated 15.92% over three months. It is not a good buy for conservative investors or those seeking stable returns.
IBRX is strictly suitable for long-term investment, with a suggested minimum holding period of 3-5 years. This is a story stock where the investment thesis will be proven over multiple quarters and years of commercial execution, pipeline development, and regulatory milestones. The stock's extreme volatility (evidenced by a 148% one-year gain and a -42% max drawdown), lack of dividends, and high cash burn make it a poor candidate for short-term trading. Only investors willing to endure significant price swings while waiting for the fundamental story to unfold should consider a position.